ALLMedicine™ Anaplastic Large Cell Lymphoma Center
Research & Reviews 969 results
https://doi.org/10.1007/s12325-023-02470-9
Advances in Therapy; Elsea D, Savage KJ et. al.
Mar 16th, 2023 - Brentuximab vedotin versus physician's choice of methotrexate (MTX) or bexarotene (BEX) significantly improved progression-free survival (PFS) (median PFS, 16.7 vs. 3.5 months) and delayed time to subsequent treatment (8.4 vs. 3.7 months), with si...
https://doi.org/10.1016/j.beha.2023.101440
Best Practice & Research. Clinical Haematology; Xavier AC, Suzuki R et. al.
Mar 13th, 2023 - Mature B-cell lymphomas, (B- or T-cell) lymphoblastic lymphomas (LBL), and anaplastic large cell lymphoma (ALCL) correspond to about 90% of all non-Hodgkin lymphoma (NHL) cases occurring in children and adolescents. The remaining 10% encompass a c...
https://doi.org/10.1016/j.beha.2023.101444
Best Practice & Research. Clinical Haematology; Rigaud C, Knörr F et. al.
Mar 13th, 2023 - Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) is a CD30-positive T cell lymphoma characterized by signalling from constitutively activated ALK fusion proteins. Most children and adolescents present in advanced sta...
https://doi.org/10.1016/j.beha.2023.101448
Best Practice & Research. Clinical Haematology; Stokke J, Tann A et. al.
Mar 13th, 2023 - Cutaneous lymphomas and lymphoid proliferations (LPD) in children, adolescents, and young adults (CAYA) are a heterogeneous group of lymphoid neoplasms that present formidable diagnostic challenges to clinicians and pathologists alike. Although ra...
https://clinicaltrials.gov/ct2/show/NCT01979536
Mar 10th, 2023 - PRIMARY OBJECTIVES: I. To determine the tolerability of brentuximab vedotin given in combination with standard chemotherapy (anaplastic large cell lymphoma [ALCL]99) and to determine the tolerability of crizotinib given in combination with chemoth...
Guidelines 6 results
https://doi.org/10.6004/jnccn.2022.0015
Journal of the National Comprehensive Cancer Network : JN... Horwitz SM, Ansell S et. al.
Mar 12th, 2022 - Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by ang...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894347
British Journal of Haematology; Turton P, El-Sharkawi D et. al.
Nov 23rd, 2020 - Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast implants and new breast sy...
https://doi.org/10.1016/j.anndiagpath.2020.151623
Annals of Diagnostic Pathology; Vega F, Amador C et. al.
Sep 19th, 2020 - The diagnosis of T-cell lymphomas is highly challenging and requires an integrated approach in which clinical, morphologic, immunophenotypic and molecular data are incorporated into the diagnosis. Under the auspices of the American Registry of Pat...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106983
Journal of Clinical Oncology : Official Journal of the Am... Jaffe ES, Ashar BS et. al.
Feb 12th, 2020 - To provide guidelines for the accurate pathologic diagnosis of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), the preoperative evaluation of the patient with suspected BIA-ALCL, and the pathologic evaluation of the capsulecto...
https://doi.org/10.1093/asj/sjw259
Aesthetic Surgery Journal; Clemens MW, Horwitz SM
Feb 12th, 2017 - Published case series demonstrate a lack of treatment standardization for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) with a wide variety of therapeutic strategies being employed at all stages of disease. The National Compr...
Drugs 3 results see all →
Clinicaltrials.gov 78 results
https://clinicaltrials.gov/ct2/show/NCT01979536
Mar 10th, 2023 - PRIMARY OBJECTIVES: I. To determine the tolerability of brentuximab vedotin given in combination with standard chemotherapy (anaplastic large cell lymphoma [ALCL]99) and to determine the tolerability of crizotinib given in combination with chemoth...
https://clinicaltrials.gov/ct2/show/NCT04447027
Mar 9th, 2023 - Background: Mature T-cell malignancies (TCM) are rare and heterogeneous group of leukemias and lymphomas accounting for 5 to 10% of all lymphomas in the US Patients with systemic TCM are most commonly treated with a CHOP (cyclophosphamide, doxorub...
https://clinicaltrials.gov/ct2/show/NCT04094610
Mar 9th, 2023 - Enrollment of subjects into Phase 1 will proceed concurrently by age as follows: Subjects <12 years old will initially be enrolled in the Phase 1 part to determine the pediatric RP2D for this age group; once the pediatric RP2D is determined, subje...
https://clinicaltrials.gov/ct2/show/NCT04213209
Feb 13th, 2023 - The drug being tested in this survey is called Brentuximab Vedotin intravenous infusion 50 mg. This intravenous infusion is being tested to treat adult patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma (PTCL) (excluding...
https://clinicaltrials.gov/ct2/show/NCT05017337
Jan 19th, 2023 - BASILICA is a translational research study being undertaken at The Royal Marsden NHS Foundation Trust that aims to investigate aetiology of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), capsular contracture (CC) as well as t...
News 252 results
https://www.mdedge.com/hematology-oncology/article/260233/breast-cancer/breast-cancer-postmastectomy-implant-reconstruction
Dec 19th, 2022 - Key clinical point: The relative risk for anaplastic large cell lymphoma (ALCL) was significantly increased in women who underwent implant reconstruction after mastectomy for breast cancer (BC) or ductal carcinoma in situ. Major finding: The relat.
https://www.onclive.com/view/fda-grants-fast-track-designation-to-mt-101-for-cd5-relapsed-refractory-ptcl
Nov 21st, 2022 - The FDA has granted a fast track designation to MT-101 for use as a potential therapeutic option in patients with relapsed or refractory, CD5-positive peripheral T-cell lymphoma (PTCL), according to an announcement from Myeloid Therapeutics, Inc.1...
https://www.mdedge.com/fedprac/avaho/article/257685/lymphoma-plasma-cell-disorders/b-t-case-concurrent-b-cell-and-t-cell
John Esther, Shashank Sama et. al.
Sep 9th, 2022 - Background Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive type of non- Hodgkin lymphoma (NHL), comprising 30% of all NHL. Due to a decreased state of immunosurveillance resulting from the disease itself and its associated ther.
https://www.onclive.com/view/tolinapant-displays-encouraging-activity-and-safety-in-relapsed-refractory-ptcl-ctcl
Aug 31st, 2022 - Single-agent tolinapant (ASTX660) generated promising response rates with a manageable safety profile in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL), according to data from the phase 2 A...
https://www.onclive.com/view/brentuximab-vedotin-boosts-survival-in-adult-and-aya-patients-with-advanced-hodgkin-lymphoma
Jul 21st, 2022 - Findings from recent studies have demonstrated the value of brentuximab vedotin (Adcetris) in both adult and adolescent and young adult (AYA) patients with advanced Hodgkin lymphoma, Ann S. LaCasce, MD, MMSC, said during a presentation at the 2022...